Bliv, a leading provider of GLP-1 weight loss solutions for diabetic and obese Americans, announced today their plans to raise capital in a seed round. Since opening doors in early 2023, Bliv has quickly gained traction with thousands of patients across almost every state in the US.
"We are thrilled to see such rapid growth and success with our GLP-1 weight loss program," said Scott Jones, Cofounder and CEO of Bliv. "But we don't want to stop there. We have big plans to expand our telemedicine provider network and offer new services that address other health concerns in this market."
Bliv's seed round will be used to expand their national telemedicine provider network, allowing them to reach more patients in need of their weight loss solutions. The funding will also support the expansion of services such as functional medicine, bioidentical hormone replacement therapy, specialized testing, sexual health and virtual urgent care.
"We have observed successful solutions like Ro, Calibrate, Sequence (Weight Watchers), Hims, and One Medical (Amazon) and plan to offer similar services in this marketplace," added Jones.
Bliv's goal is to become a premiere provider of not only GLP-1 weight loss solutions but also other telemedicine services in the US. With their unique approach to healthcare and focus on patient satisfaction, Bliv is poised for further growth and success in the market.
For more information about Bliv and their current fundraising efforts, please contact Scott Jones at scott.jones@joinbliv.com. Join us as we revolutionize telemedicine and make a positive impact on the health of millions of Americans. #JoinBliv #HealthRevolution #SeedRoundFunding #BlivForward
You can find out if you qualify for GLP-1 medication in less than 5 minutes by taking our weight-loss quiz.
Take the Quiz